Target intelligence / Profile preview

Immunoglobulin lambda variable (VI)-22-1 (IGLV(VI)-22-1)

Target
IGLV(VI)-22-1
Molecular classification
Immunoglobulin variable light chain, Immunoglobulin lambda variable region, Antibody domain
01

Overview

Immunoglobulin lambda variable (VI)-22-1 encodes a variable region of the lambda light chain of immunoglobulins (antibodies)[5][3]. This domain contributes to antigen recognition and binding, forming part of the antigen-specific binding site together with the variable region of the heavy chain[2][3]. The lambda light chain is encoded at chromosome 22q11.2 and comprises multiple variable region genes with distinct subgroups[5][1]. Antibodies are composed of two heavy and two light chains (in humans, either kappa or lambda type), and each B cell expresses only one light chain class[3][1]. The immunoglobulin variable regions are generated by somatic recombination and hypermutation, ensuring immune diversity and specificity[1][3]. Lambda light chains, including the variable region encoded by IGLV(VI)-22-1, are important in both normal immune function and in disease contexts such as lymphoid malignancies and plasma cell dyscrasia, where changes in their expression are clinically relevant[3][1].

Other names
Immunoglobulin lambda variable VI-22-1IGLV(VI)-22-1Lambda variable VI-22-1IGLV
02

Biological functions

Antigen bindingAdaptive immune response
03

Disease associations

CancerInflammationInfection
04

Safety considerations

no safety concerns for the gene itself; excess free lambda light chains can cause kidney damage in multiple myeloma
05

Biomarkers

Free immunoglobulin lambda light chains as Bence Jones protein in urine (for monitoring multiple myeloma)B-cell clonal markers by immunohistochemistry (kappa/lambda ratio to diagnose lymphoid malignancies)

Beyond the preview

Go deeper on Immunoglobulin lambda variable (VI)-22-1 (IGLV(VI)-22-1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunoglobulin lambda variable (VI)-22-1 (IGLV(VI)-22-1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call